The Journal of Immunology · 1982 · 35 citations · 0 references
Life SciencesImmunologyAutoimmunityClinical ImmunologyMonoclonal AntibodiesAntibody-antigen RecognitionAutoantibodiesAutoantigensAutoimmune DiseasesSystemic Autoimmune DiseaseSystemic Lupus ErythematosusMixed Lymphocyte ReactionSystemic Lupus Erythematosus Associations
Abstract In this report, we examined the effect of SLE sera on the autologous MLR and found that sera from active SLE patients contain an IgG antibody that blocks the autologous MLR. Sera from 12 patients with active SLE caused 84 ± 5% inhibition of the autologous MLR vs 19 ± 11% inhibition caused by sera from 12 patients with inactive disease (mean ± SE, p < 0.001). When three SLE sera were separated into IgG and IgM fractions using affinity chromatography, the MLR inhibitory activity was contained in the IgG fraction (whole sera, 93 ± 8% inhibition; IgG fraction, 79 ± 16% inhibition; IgM fraction, 9 ± 18% inhibition), whereas anti-la blocking activity was present in both fractions. Inhibitory activity of SLE sera on the autologous MLR was highly correlated with ability of such sera to block the binding of monoclonal anti-la antibody to la-positive target cells (n = 24, r = 0.84, p < 0.001 ). Absorption of SLE sera with la-positive but not la-negative cell lines eliminated both the inhibition of the autologous MLR (91 ± 10% inhibition by whole sera; 11 ± 18% inhibition by sera absorbed with la(+) cell line; 73 ± 23% inhibition absorbed with la(–) cell line) and the blocking activity of monoclonal anti-la binding to la-positive target cells. We conclude that both IgG and IgM antibodies present in the sera of patients with active SLE block the binding of monoclonal anti-la to la-positive target cells and that IgG antibody blocks the autologous MLR and may be responsible for the depressed autologous MLR seen in patients with this disease.